What Are AstraZeneca plc’s Dividend Prospects Like Beyond 2014?

Royston Wild looks at the long-term payout potential of AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at pharmaceuticals giant AstraZeneca‘s (LSE: AZN) (NYSE: AZN.US) dividend outlook past 2014.

Dividend outlook in the sick bay

AstraZeneca has faced a continued backdrop of profits pressure in recent years, as the effects of patent expirations across many of its key products — not to mention the firm’s belated measures to address this issue — have whacked revenues.

As a consequence, AstraZeneca is expected to post a second-consecutive annual earnings drop in 2013 — results for which are due on Thursday 6 February — with a huge 23% decline. Analysts expect the situation to gradually improve over the medium term, although earnings declines of 8% and 2% for 2014 and 2015 correspondingly indicate enduring sales problems.

Although full-year dividends have advanced at a compound annual growth rate of 8.1% since 2008, AstraZeneca was forced to keep the dividend on hold in 2012 in line with earnings weakness. And the prospect of fresh pressure on the bottom line is anticipated to hinder near-term growth.

Indeed, analysts expect the payout to increase just 0.8% in 2013 to 282.1 US cents per share, with an additional 1% rise predicted this year to 284.9 cents. But the shareholder payment is expected to dip in 2015 to 282.7 cents, a 0.8% drop.

It is worth bearing in mind that anticipated payments for this year and next still result in bubbly yields of 4.5% and 4.4% respectively, crushing the FTSE 100 of 3.1%. However, investors should be mindful that dividend cover comes through 2015 comes in at just 1.6 times prospective earnings, comfortably below the widely-considered security threshold of 2 times. This could be a significant issue should earnings collapse below expectations.

As well, the company’s cash situation also continues to deteriorate as a result of declining profits, another worrying omen for dividend funding. Although the firm punched free cash flow of $4.79bn during the first nine months of 2013, this was down substantially from $5.8bn during the corresponding 2012 period.

Indeed, capital flows were affected by the substantial amounts of capital being ploughed into R&D in order to rejuvinate its flagging drugs pipeline — capital expenditure jumped more than 40% to $1.89bn during January-September.

The drugs specialists are taking massive steps in order to facilitate future growth, from the establishment of new research bases across the globe through to making significant acquisitions to kickstart its organic product development. The company received a fillip in recent days when its Xigduo diabetes medicine was the latest in its line of products to be given the green light, this time for sale in Europe.

But in my opinion AstraZeneca still has some way to go to boost its drugs portfolio and compensate for patent expirations across its big sales drivers, and I believe that dividends could come under the cosh should earnings continue to drag heavily.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Royston does not own shares in AstraZeneca.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »